Effects and safety of Korodin Herz-Kreislauf-Tropfen on moderate hypotension and influence on cognitive functions in adults
Phase 1
- Conditions
- moderate low blood pressureTherapeutic area: Psychiatry and Psychology [F] - Psychological processes [F02]
- Registration Number
- EUCTR2017-003264-13-DE
- Lead Sponsor
- Robugen GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
moderate low blood pressure
Subjects must have moderate low blood pressure but be otherwise healthy as judged on the Basis of a medical examination
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 120
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
no low blood pressure
other medications, alcohol
if female: pregnancy
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s): Change of moderate low blood pressure;Timepoint(s) of evaluation of this end point: Change of moderate low blood pressure<br>before - meanwhile and after Trial - 1,3,7,15 minutes after oral intake
- Secondary Outcome Measures
Name Time Method Secondary end point(s): Change of cognitive and mental functions;Timepoint(s) of evaluation of this end point: immediately after trial 15 and 30 minutes